ArticlePharmacoepidemiology and drug safety2026
Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada.
Article in Pharmacoepidemiology and drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care COVID-19 Encounter: A Retrospective Cohort Study From Alberta, Canada.Pharmacoepidemiology and drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo describe the characteristics of adults who had a severe coronavirus disease 2019 (COVID-19) outcome during a timeframe that nirmatrelvir/ritonavir (NMV-r; Paxlovid) was available, to assess medical eligibility and receipt of NMV-r before presentation to acute care.
methodsPopulation-level administrative data was used to describe adults (≥ 18 years) who had an acute care COVID-19 encounter (hospitalization or emergency department visit with COVID-19) between January 2022 and March 2023 in Alberta, Canada.
resultsThe 30 793 adults had an acute care COVID-19 encounter; among the 8345 (27.1%) who were assessed as medically eligible for NMV-r, 8111 (97.2%) did not receive outpatient NMV-r ≤ 30 days before the encounter. During the acute care COVID-19 encounter, the proportion who had an all-cause death was 4.7% (received prior NMV-r treatment) and 6.6% (did not) among those who were medically eligible for NMV-r. Of those medically eligible for NMV-r who were hospitalized (n = 4495), the mean length of stay was 9.7 days (SD 11.1) in NMV-r treated and 15.3 days (SD 25.9) in untreated, and the proportion admitted to the intensive care unit was 2.1% in NMV-r treated and 7.6% in untreated.
conclusionResults from this real-world study show that most adults with an acute care COVID-19 encounter who were assessed as medically eligible for NMV-r at the time of presentation had not received this outpatient treatment beforehand in Alberta, Canada, suggesting a potential care gap. If gaps are closed, strain on the acute healthcare system can be alleviated, with attendant improvement in other important patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.